A Study of ALPN-303 in Adult Healthy Volunteers

Healthy Volunteers Clinical Trial

— RUBY-1  

Official title:

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303 in Adult Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05034484
• Other study ID #: AIS-D01
• Status: Completed
• Phase: Phase 1
• Start date: November 15, 2021
• Est. completion date: February 27, 2023

Study information

• Verified date: May 2023
• Source: Alpine Immune Sciences, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to assess the safety, tolerability, pharmacokinetics (the amount of drug in the blood), pharmacodynamics (how the drug effects the body) and immunogenicity (how the drug effects the immune system) of a single dose of an investigational drug called ALPN-303. Multiple dose levels will be tested.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: February 27, 2023
• Est. primary completion date: February 27, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Summary of Inclusion Criteria:

• Able and willing to provide written informed consent

• Body mass index 18 to 32 kg/m2

• Agree to avoid strenuous physical activity for 2 days prior to each study visit

• Agree to use highly effective contraception during the study (all participants) and for 90 days after study drug dosing (males) or for 60 days after study drug dosing (females)

• Male participants must refrain from donating sperm during the study and for 90 days after study drug dosing

• Female participants must not be pregnant or breastfeeding and must refrain from donating ova during the study and for 60 days after study drug dosing

• Must have completed vaccination against SARS-CoV-2 at least 4 weeks prior to study drug dosing

Summary of Exclusion Criteria:

• Any current disease, condition, or treatment that could interfere with the study, interfere with interpretation of the data, or pose an unacceptable risk to the participant

• History or symptoms of significant psychiatric disease; mild, resolved depression or anxiety is acceptable

• History of immunological disorders, auto-immune disorders, acquired or congenital immune deficiency; see protocol for clarifications/exceptions

• History of significant hepatic or renal disease or impairment

• Evidence of an active or suspected cancer or a history of malignancy within the previous 3 years; see protocol for exceptions

• History of major organ transplantation with an existing functional graft

• Use or receipt of prescription medications, over-the-counter medications, herbal remedies, or investigation products (study drugs) within protocol-defined timeframes prior to study entry; hormone replacement therapy initiated at least 2 months prior to Screening is acceptable

• Significant loss of blood or blood product (including donation) over 500 mL or transfusion of any blood product during Screening or within 3 months of Screening

• Unwilling to refrain from alcohol use = 48 hours prior to Study Day -1.

• Known hypersensitivity, allergy, or intolerance to ALPN-303, Fc-based biologic therapy, or any of the excipients contained in the ALPN-303 formulation

• Immunization with any live vaccine within 6 weeks prior to study drug administration, or expected to require any live vaccines during the study or within 6 weeks after receiving study drug

• Acceptable laboratory assessments at Screening and Day -1

• Positive screen for drugs of abuse or alcohol at Screening or Day -1

• Positive tests for infectious disease (HIV, hepatitis B, hepatitis C, SARS-CoV-2)

• Acute infection during or within 4 weeks prior to Screening

• History of frequent or atypical infections as defined per protocol; signs or symptoms of immunodeficiency

• History or presence of any chronic infectious condition

• Cardiac risk factors, as defined per protocol

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• ALPN-303
Multiple dose levels will be evaluated.
• Placebo
Placebo will be administered

Locations

Country	Name	City	State
Australia	Investigative Site	Brisbane	Queensland
Australia	Investigative Site	Melbourne	Victoria

Sponsors (1)

Lead Sponsor	Collaborator
Alpine Immune Sciences, Inc.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment-emergent Adverse Events (TEAE)	Type, incidence, and severity of TEAE as assessed by CTCAE	Day 1 through Day 30